Scarica l'app Stockscreener
3.20
1.27%
0.04
Dopo l'orario di chiusura:
3.27
0.07
+2.19%
Precedente Chiudi:
$3.16
Aprire:
$3.13
Volume 24 ore:
1.80M
Relative Volume:
2.96
Capitalizzazione di mercato:
$215.02M
Reddito:
-
Utile/perdita netta:
$-19.20M
Rapporto P/E:
-0.7674
EPS:
-4.17
Flusso di cassa netto:
$-15.98M
1 W Prestazione:
-6.98%
1M Prestazione:
+61.62%
6M Prestazione:
+123.78%
1 anno Prestazione:
+151.97%
Intervallo 1D:
$3.07
$3.50
Intervallo di 1 settimana:
$3.07
$4.20
Portata 52W:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Nome
Inhibikase Therapeutics Inc
Settore
Industria
Telefono
678-392-3419
Indirizzo
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Confronta IKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
3.20 | 215.02M | 0 | -19.20M | -15.98M | -3.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress
Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com
Inhibikase Therapeutics Terminates At the Market Offering Agreement - Defense World
Inhibikase Therapeutics ends agreement with sales agent By Investing.com - Investing.com Canada
Inhibikase Therapeutics ends agreement with sales agent - Investing.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% – What’s Next? - Defense World
Inhibikase Therapeutics (NYSE:IKT) Shares Up 7%Here's Why - MarketBeat
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks
ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy
Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian
Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey
Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com
Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India
Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Australia
Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India
Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa
Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com
Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance
Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com
Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN
IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan
Inhibikase Therapeutics Closes of $275 Million Financing - citybiz
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Inhibikase Therapeutics’ $110 Million Private Placement - Global Legal Chronicle
Analyzing the Impact of Earnings Reports on Inhibikase Therapeutics Inc Inc. (IKT) Price Performance - The InvestChronicle
500: Something went wrong - Investing.com
Inhibikase Therapeutics Secures $110M for Drug Development - Yahoo Finance
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) expanding its growth trajectory ahead - SETE News
Inhibikase Therapeutics, Inc. Announces Pricing of $110 Million Private Placement - Marketscreener.com
Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inhibikase Therapeutics Inc Azioni (IKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):